

December 25, 2024

Press Release

iXgene Inc.
C4U Corporation

**iXgene and C4U have executed a collaborative research agreement
for a novel cell therapy product utilizing CRISPR-Cas3 and iPSC**

- iXgene Inc. (“iXgene”) and C4U Corporation (“C4U”) have executed a collaborative research agreement.
- In this research collaboration, both parties will conduct non-clinical studies of a novel cell therapy by using iXgene’s iPSC cells platform with C4U’s CRISPR-Cas3 gene editing technology.
- Under the terms of the agreement, C4U will receive an upfront payment. In addition, C4U has granted iXgene the right to negotiate an exclusive patent license for the further development of gene-edited iPSC cell-derived products generated from this research collaboration. Additional terms of the agreement are not disclosed.

About iXgene Inc.

iXgene, a biotech company established in 2020 from Keio University School of Medicine, is dedicated to developing groundbreaking treatments for intractable diseases using genome-edited iPSC cells. This innovative technology merges iPSC cell with genome editing to tackle unmet medical needs.

iXgene is developing genome-edited iPSC cell-derived neural stem cells (therapeutic NSC), an innovative cell therapy. This therapy combines the migratory ability of neural stem cells with a novel suicide gene to enable localized production of high concentrations of anti-cancer agents. iXgene is currently advancing the development of this treatment globally for patients with malignant brain tumors.

About C4U Corporation

C4U is a privately held biotech company based in Osaka, Japan, and is focused on the development of safe and efficient gene therapies utilizing its proprietary next generation CRISPR-Cas3 gene editing platform. In comparison to the CRISPR-Cas9 platform, CRISPR-Cas3 presents the distinct benefits of: 1) no off-target by the higher selectivity of deletion site (improved safety); 2) efficient knockouts by the larger deletion of gene sequences; and 3) an entirely independent patent portfolio. C4U has been granted a worldwide exclusive license to CRISPR-Cas3 by Osaka University for use in eukaryotic cells thus simplifying sublicensing transactions which is in sharp contrast to the complex and heavily litigated CRISPR-Cas9 patent landscape.

Contact Information

iXgene Inc.

Address : Yotsuya 1-14-1, Shinjuku, Tokyo 160-0004, Japan

E-mail : info@ixgene.inc

URL : <https://www.ixgene.inc/>

C4U Corporation

Address : Yamadaoka 2-8, Suita, Osaka 565-0871, Japan

E-mail : info@crispr4u.com

URL : <https://www.crispr4u.jp/en/>